SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 72935.
  • 2
    Storb R, Deeg HJ, Pepe M et al. Methotrexate and cyclosporine versus cyclosporine alone for propylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 1989; 73: 172934.
  • 3
    Sayer HG, Longton G, Bowden R, Pepe M, Storb R. Increased risk of infection in marrow transplant patients receiving methylprednisolone for graft-versus-host disease prevention. Blood 1994; 84: 132832.
  • 4
    Ferrara JL, Levy R, Chao NJ. Pathophysiologic mechanisms of acute graft-versus-host disease. Biol Blood Marrow Transplant 1999; 5: 34756.
  • 5
    Ferrara JL, Holler E, Blazar B. Monoclonal antibody receptor antagonist therapy for GVHD. Cancer Treat Res 1999; 101: 33168.
  • 6
    Depper JM, Leonard WJ, Robb RJ, Waldmann TA, Greene WC. Blockade of the interleukin-2 receptor by anti-Tac antibody: inhibition of human lymphocyte activation. J Immunol 1983; 131: 6906.
  • 7
    Kupiec-Weglinski JW, Diamantstein T, Tilney NL, Strom TB. Therapy with monoclonal antibody to interleukin 2 receptor spares suppressor T cells and prevents or reverses acute allograft rejection in rats. Proc Natl Acad Sci USA 1986; 83: 26247.
  • 8
    Brown PS Jr, Parenteau GL, Dirbas FM et al. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival. Proc Natl Acad Sci USA 1991; 88: 26637.
  • 9
    Queen C, Schneider WP, Selick HE et al. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA 1989; 86: 1002933.
  • 10
    Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP for the CHIB 201 International Study Group. Randomized trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997; 350: 11938.
  • 11
    Vincenti F, Nashan B, Light S for the Double Therapy and the Triple Therapy Study Groups. Daclizumab: outcome of phase III trials and mechanism of action. Transplant Proc 1998; 30: 21558.
  • 12
    Calmus Y, Scheele JR, Gonzalez-Pinto I et al. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transpl 2002; 8: 12331.
  • 13
    Niemeyer G, Koch M, Light S, Kuse ER, Nashan B. Long-term safety, tolerability and efficacy of daclizumab (Zenapax®) in a two-dose regimen in liver transplant recipients. Am J Transplant 2002; 2: 45460.
  • 14
    Kahan BD, Rajagopalan PR, Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Transplantation 1999; 67: 27684.
  • 15
    Anasetti C, Hansen JA, Waldman TA et al. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood 1994; 84: 13207.
  • 16
    Przepiorka D, Kernan NA, Ippoliti C et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 2000; 95: 839.
  • 17
    Willenbacher W, Basara N, Blau IW, Fauser AA, Kiehl MG. Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab. Br J Haematol 2001; 112: 8203.
  • 18
    Massenkeil G, Rackwitz S, Genvresse I, Rosen O, Dorken B, Arnold R. Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplant 2002; 30: 899903.
  • 19
    Huber C, Fink U, Leibold W et al. The role of adherent HLA-DR+ mononuclear cells in autologous and allogeneic MLR. J Immunol 1981; 127: 72631.
  • 20
    Zier K, Huber C, Braunsteiner H. Linear density gradient separation of human lymphocyte subsets. I. Analysis by mixed lymphocyte culture and cell mediated lympholysis responses. Eur J Immunol 1977; 7: 36670.
  • 21
    Kaminski E, Hows J, Man S et al. Prediction of graft versus host disease by frequency analysis of cytotoxic T cells after unrelated donor bone marrow transplantation. Transplantation 1989; 48: 60813.
  • 22
    Kircher B, Stevanovic S, Urbanek M et al. Induction of HA-1-specific cytotoxic T cell clones parallels the therapeutic effect of donor lymphocyte infusion (DLI). Br J Haematol 2002; 117: 9359.
  • 23
    Kovarik JM, Rawlings E, Sweny P et al. Prolonged immunosuppressive effect and minimal immunogenicity from chimeric (CD25) monoclonal antibody SDZ CHI 621 in renal transplantation. Transplant Proc 1996; 28: 9134.
  • 24
    Kovarik JM, Gerbeau C, Legay F, Nashan B, Hall M. Soluble interleukin-2 receptor (sIL-2R) profiles in kidney and liver transplant patients receiving basiliximab (Simulect). Transplantation 1999; 67: S196.
  • 25
    Vincenti F. Interleukin-2 receptor monoclonal antibodies in renal transplantation: current use and emerging regimens. Transplant Proc 2001; 33: 316971.
  • 26
    Tellides G, Dallman MJ, Morris PJ. Synergistic interaction of cyclosporine A with interleukin 2 receptor monoclonal antibody therapy. Transplant Proc 1998; 20 (Suppl. 2):2026.
  • 27
    Kupiec-Weglinski JW, Hahn HJ, Kirkman RL et al. Cyclosporine potentiates the immunosuppressive effects of anti-interleukin 2 receptor monoclonal antibody therapy. Transplant Proc 1998; 20 (Suppl. 2):20716.
  • 28
    Weiss L, Reich S, Slavin S. The role of antibodies to IL-2 receptor and Asialo GM1 on graft-versus-leukemia effects induced by bone marrow allografts in murine B cell leukemia. Bone Marrow Transplant 1995; 16: 45761.
  • 29
    Montagna D, Yvon E, Calcaterra V et al. Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro anti-leukemia and antiviral activity. Blood 1999; 93: 35507.
  • 30
    André-Schmutz I, Le Deist F, Hacein-Bey-Abina S et al. Immune reconstitution without graft-versus-host disease after hematopoietic stem-cell transplantation: a phase 1/2 study. Lancet 2002; 360: 1307.
  • 31
    Champlin RE, Passweg JR, Zhang MJ et al. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood 2000; 95: 39964003.